Niu Xue-Hua, Wu Peng-Fei, Hua Hai-Yong, Huang Li-Hua, Wu Hang-Yuan, Zhu Hong-Ying, Yang Xiao-Juan, Yao Shang-Zhi, Li Yan-Guang, Qiu Yuan-Wang
Third Hospital of Kunshan, Jiangsu Province, Kunshan 215300, China.
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2011 Dec;23(6):701-3.
To evaluate the therapeutic effect and safety of Dahuangzhechong pills on advanced schistosomiasis.
Sixty-two patients with advanced schistosomiasis were divided randomly into two groups, a treatment group and a control group, and treated with Dahuangzhechong pills and routine therapy, respectively. The course of treatment was 52 weeks in the two groups. Before and after the 52-week treatment, the indexes of liver function and hepatic fibrosis, prothrombin time (PT), Child-Pugh scores and changes of B-type ultrasonic images were detected for all the patients.
There were significant differences in the levels of alanine aminotransferase (ALT) and total bilirubin (TBIL), the indexes of hepatic fibrosis, portal venous inside diameters and portal venous flow between the two groups after 52 weeks treatment (P < 0.05). In addition, there were no obvious adverse effects during the treatment in the patients of the Dahuangzhechong pill group.
Dahuangzhechong pill treatment is a safe and effective therapy for the patients with advanced schistosomiasis.
评估大黄蛰虫丸治疗晚期血吸虫病的疗效及安全性。
将62例晚期血吸虫病患者随机分为两组，即治疗组和对照组，分别给予大黄蛰虫丸及常规疗法治疗。两组疗程均为52周。治疗52周前后，对所有患者检测肝功能、肝纤维化指标、凝血酶原时间（PT）、Child-Pugh评分及B型超声图像变化。
治疗52周后，两组间丙氨酸氨基转移酶（ALT）、总胆红素（TBIL）水平、肝纤维化指标、门静脉内径及门静脉血流存在显著差异（P<0.05）。此外，大黄蛰虫丸组患者治疗期间无明显不良反应。
大黄蛰虫丸治疗晚期血吸虫病患者安全有效。
